EUVIMEDEUVIMED entdecken
Leserbrief

Reply to Singh and Srivastav’s Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. 2026;12:393–402

Amy Lockefeer, Arianne Schild, Swapneel Anaokar, Mikkel Fode

European Urology Focus · 2026-06 · 12 (3) · 622-623

DOI: 10.1016/j.euf.2026.04.011 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Urology Focus, 2026-06. Verfasst von Amy Lockefeer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Global Development, Inc., Northbrook, IL, USA. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Astellas Pharma US Inc, Astellas Pharma.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Astellas Pharma Global Development, Inc., Northbrook, IL, USA.
  • Astellas Pharma Europe Ltd, Addlestone, UK. Electronic address: swapneel.anaokar@astellas.com.
  • Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Förderung

  • Astellas Pharma US Inc
  • Astellas Pharma

Zitieren

APA

Lockefeer, A., Schild, A., Anaokar, S., & Fode, M. (2026). Reply to Singh and Srivastav’s Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. 2026;12:393–402. European Urology Focus, 12(3), 622-623. https://doi.org/10.1016/j.euf.2026.04.011

Vancouver

Lockefeer A, Schild A, Anaokar S, Fode M. Reply to Singh and Srivastav’s Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. 2026;12:393–402. European Urology Focus. 2026;12(3):622-623. doi:10.1016/j.euf.2026.04.011

BibTeX
@article{Lockefeer2026,
  author = {Lockefeer, Amy and Schild, Arianne and Anaokar, Swapneel and Fode, Mikkel},
  title = {Reply to Singh and Srivastav’s Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. 2026;12:393–402},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {3},
  pages = {622--623},
  doi = {10.1016/j.euf.2026.04.011}
}
Kostenlos starten →